CLRB
Cellectar Biosciences, Inc. NASDAQ Listed Nov 10, 2005$2.56
-0.19%
vs $2.57
Mkt Cap $8.2M
52w Low $2.20
4.6% of range
52w High $10.19
50d MA $2.84
200d MA $3.46
P/E (TTM)
—
EV/EBITDA
—
P/B
0.7x
Debt/Equity
0.0x
ROE
-255.3%
P/FCF
-0.3x
RSI (14)
39.00
ATR (14)
$0.23
Beta
0.40
50d MA
$2.84
200d MA
$3.46
Avg Volume
223.8K
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
100 Campus Drive · Florham Park, NJ 07932 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | BMO | -1.19 | -0.53 | +55.5% | 2.90 | +0.7% | -4.5% | -0.4% | -0.4% | +10.9% | -3.0% | — |
| Nov 13, 2025 | BMO | -1.91 | -1.41 | +26.2% | 2.87 | -1.0% | +1.0% | +0.7% | +5.1% | -6.8% | -1.4% | — |
| Aug 14, 2025 | BMO | -3.60 | -3.39 | +5.8% | 4.42 | -0.5% | -1.8% | +8.3% | -4.3% | -2.0% | +1.8% | — |
| May 13, 2025 | BMO | -5.11 | -3.90 | +23.7% | 7.20 | +1.7% | +0.3% | +5.4% | -3.4% | +4.4% | +3.3% | — |
| Mar 13, 2025 | BMO | -0.38 | -0.01 | +97.4% | 8.99 | -0.6% | +5.3% | +6.7% | +12.0% | +2.3% | -1.5% | — |
| Oct 29, 2024 | BMO | -0.37 | -0.51 | -37.8% | 61.50 | -0.5% | +0.0% | -0.5% | -0.5% | +0.0% | +0.0% | — |
| Aug 13, 2024 | BMO | -0.23 | -0.73 | -217.4% | 60.60 | +0.5% | -1.0% | +1.5% | +0.0% | +1.0% | +1.5% | — |
| May 14, 2024 | BMO | -0.50 | -0.40 | +20.0% | 95.40 | +2.2% | +5.7% | -0.9% | -0.9% | -4.2% | +2.8% | — |
| Mar 27, 2024 | BMO | -0.59 | -0.66 | -11.9% | 109.20 | +5.2% | +9.3% | -1.5% | +1.8% | -0.3% | -6.5% | — |
| Nov 13, 2023 | BMO | -13.21 | -24.62 | -86.4% | 62.10 | +1.0% | -2.4% | -2.0% | +1.0% | +4.0% | +3.8% | — |
| Aug 14, 2023 | BMO | -0.69 | -0.73 | -5.8% | 48.90 | -1.8% | +4.9% | -4.1% | -2.4% | +0.6% | +2.5% | — |
| May 4, 2023 | BMO | -0.75 | -0.76 | -1.3% | 44.40 | -1.4% | -1.4% | -0.7% | -2.1% | -1.4% | +0.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15 | Ladenburg Thalmann | Initiates | Buy | $10 | $3.20 | $3.26 | +1.9% | -3.4% | +1.6% | -2.5% | +3.6% | +0.0% |
| Mar 10 | Maxim Group | Upgrade | Hold → Buy | — | $2.75 | $2.84 | +3.3% | +10.9% | -3.0% | +9.1% | -0.9% | +2.2% |
| May 14 | Maxim Group | Downgrade | Buy → Hold | — | $7.20 | $7.32 | +1.7% | +0.3% | +5.4% | -3.4% | +4.4% | +3.3% |
| Dec 11 | Oppenheimer | Downgrade | Outperform → Perform | — | $38.40 | $12.87 | -66.5% | -76.1% | -13.5% | -1.5% | -0.9% | +1.8% |
| Nov 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $53.10 | $52.50 | -1.1% | -9.0% | -3.1% | +1.3% | +0.0% | -0.6% |
| Mar 28 | Roth MKM | Maintains | Buy → Buy | — | $109.20 | $114.90 | +5.2% | +9.3% | -1.5% | +1.8% | -0.3% | -6.5% |
| Mar 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $109.20 | $114.90 | +5.2% | +9.3% | -1.5% | +1.8% | -0.3% | -6.5% |
| Mar 4 | Roth MKM | Maintains | Buy → Buy | — | $126.00 | $132.00 | +4.8% | +1.0% | -4.5% | -1.2% | +1.8% | -1.7% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $57.00 | $59.40 | +4.2% | -0.5% | -1.6% | +3.8% | -2.1% | +0.0% |
| Nov 25 | Maxim Group | Maintains | Buy → Buy | — | $372.00 | $372.00 | +0.0% | -2.4% | +1.7% | +2.4% | +20.6% | +28.3% |
| Nov 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $372.00 | $372.00 | +0.0% | -2.4% | +1.7% | +2.4% | +20.6% | +28.3% |
| Nov 25 | Brookline Capital | Maintains | Buy → Buy | — | $372.00 | $372.00 | +0.0% | -2.4% | +1.7% | +2.4% | +20.6% | +28.3% |
| Nov 25 | Roth Capital | Maintains | Buy → Buy | — | $372.00 | $372.00 | +0.0% | -2.4% | +1.7% | +2.4% | +20.6% | +28.3% |
| Jul 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $384.00 | $417.00 | +8.6% | +4.7% | +5.2% | +5.7% | -1.3% | +4.1% |
| Jun 23 | Maxim Group | Maintains | Buy → Buy | — | $366.00 | $387.00 | +5.7% | +5.7% | -0.8% | +2.3% | -1.5% | +0.8% |
| Sep 13 | Roth Capital | Maintains | Buy → Buy | — | $687.00 | $750.00 | +9.2% | +3.1% | +3.8% | -1.6% | +2.1% | -1.2% |
| Jul 30 | Brookline Capital | Maintains | Buy → Buy | — | $642.00 | $660.00 | +2.8% | +1.4% | +0.9% | -0.9% | -0.9% | -2.3% |
| May 2 | H.C. Wainwright | Maintains | Buy → Buy | — | $666.00 | $678.00 | +1.8% | -2.7% | +12.0% | -0.4% | -4.1% | -2.6% |
| Dec 21 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $3720.00 | $3810.00 | +2.4% | -2.4% | +0.0% | +9.9% | -3.0% | +0.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | Longcor JarrodOff | Chief Operating Officer | Buy | 8,680 | $2.88 | $25K | 20,451 | -4.58% | +1.62% |
| May 7, 2026 | CARUSO JAMES VDir/Off | Chief Executive Officer | Buy | 8,680 | $2.88 | $25K | 20,318 | -4.58% | +1.62% |
8-K
Cellectar Biosciences, Inc. -- 8-K Filing
May 14
8-K · 1.01
!! High
Cellectar Biosciences, Inc. -- 8-K 1.01: Material Agreement
Cellectar Biosciences entered into an agreement with Ladenburg Thalmann, likely for underwriting or capital raising services, potentially strengthening its financial position for clinical development.
May 8
8-K · 5.02
!!! Very High
Barinthus Biotherapeutics plc -- 8-K 5.02: Executive Change
Barinthus Biotherapeutics appointed Douglas Swirsky as Chief Financial Officer, a leadership change potentially signaling strategic financial direction for the biotech company's operations.
Apr 22
8-K
Cellectar Biosciences INC NEW -- 8-K Filing
Cellectar Biosciences advanced its cancer pipeline with Phase 1b studies for CLR 125 in triple-negative breast cancer and Waldenstrom macroglobulinemia, with initial data expected mid-2026.
Mar 4
Institutional (13F) — Top 9
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 81,884 | $208K | New | Mar 2026 |
| 2 | Riverview Capital Advisers, Llc | 10,384 | $50K | — | Mar 2026 |
| 3 | Sequoia Financial Advisors, Llc | 18,850 | $48K | Reduced | Mar 2026 |
| 4 | Ubs Group Ag | 9,647 | $25K | Added | Mar 2026 |
| 5 | Morgan Stanley | 1,020 | $3K | — | Dec 2025 |
| 6 | Td Waterhouse Canada Inc. | 63 | $154 | — | Mar 2026 |
| 7 | Fmr Llc | 10 | $25 | New | Mar 2026 |
| 8 | Us Bancorp \de\ | 3 | $9 | — | Dec 2025 |
| 9 | Danske Bank A/s | 2 | $5 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 21,235 | $69K | Feb 2026 |
| 2 | U.S. SMALL CAP PORTFOLIO | 6,137 | $20K | Jan 2026 |
| 3 | Fidelity Series Total Market Index Fund | 4,664 | $15K | Feb 2026 |
| 4 | Fidelity Total Market Index Fund | 2,064 | $7K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 200 | $654 | Feb 2026 |
Valuation
Market Cap
$8.2M
Enterprise Value
-$6.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.00x
P/B
0.67x
P/S
—
P/FCF
-0.29x
EV/EBITDA
—
Shares Out
2.6M
Financials (TTM)
Revenue
$0
Net Income
-$20.8M
EBITDA
-$20.8M
Free Cash Flow
-$23.1M
Op Cash Flow
-$23.1M
EPS Basic
$-8.35
EPS Diluted
$-7.38
EPS Forward
$-3.98
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$15.0M
Total Liab.
$5.1M
Total Equity
$9.9M
Cash
$13.2M
LT Debt
$0
Book Value/Sh
$3.80
Debt/Equity
0.04x
Current Ratio
2.96
Quick Ratio
2.96
Returns & Growth
ROE
-255.3%
ROA
-145.5%
ROIC
-222.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
+77.1%
Price Returns
2W
-1.9%
1M
+20.8%
3M
-3.4%
6M
-12.5%
12M
-59.0%
Technicals
52W High
$10.19
52W Low
$2.20
50d MA
$2.84
200d MA
$3.46
RSI (14)
39.00
ATR (14)
$0.23
Beta
0.40
Avg Volume
224K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$12.00
High
$12.00
Low
$12.00
Median
$12.00
Data updated apr 25, 2026 1:46am
· Source: financialmodelingprep.com